These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22260413)

  • 21. Statins and prostate cancer diagnosis and grade in a veterans population.
    Farwell WR; D'Avolio LW; Scranton RE; Lawler EV; Gaziano JM
    J Natl Cancer Inst; 2011 Jun; 103(11):885-92. PubMed ID: 21498780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk.
    Bonn SE; Sjölander A; Tillander A; Wiklund F; Grönberg H; Bälter K
    Int J Cancer; 2016 Jul; 139(1):50-7. PubMed ID: 26914149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum β-carotene in relation to risk of prostate cancer: the Kuopio Ischaemic Heart Disease Risk Factor study.
    Karppi J; Kurl S; Laukkanen JA; Kauhanen J
    Nutr Cancer; 2012 Apr; 64(3):361-7. PubMed ID: 22420939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    Jacobs EJ; Anderson RL; Stevens VL; Newton CC; Gansler T; Gapstur SM
    J Clin Oncol; 2016 Nov; 34(32):3880-3885. PubMed ID: 27646949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol and prostate cancer risk: a long-term prospective cohort study.
    Heir T; Falk RS; Robsahm TE; Sandvik L; Erikssen J; Tretli S
    BMC Cancer; 2016 Aug; 16():643. PubMed ID: 27535659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
    Jacobs EJ; Stevens VL; Newton CC; Gapstur SM
    Cancer Causes Control; 2012 Aug; 23(8):1289-96. PubMed ID: 22692409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study.
    Wilson KM; Kasperzyk JL; Rider JR; Kenfield S; van Dam RM; Stampfer MJ; Giovannucci E; Mucci LA
    J Natl Cancer Inst; 2011 Jun; 103(11):876-84. PubMed ID: 21586702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body mass index and prostate cancer risk in the Carotene and Retinol Efficacy Trial.
    Bonn SE; Barnett MJ; Thornquist M; Goodman G; Neuhouser ML
    Eur J Cancer Prev; 2019 May; 28(3):212-219. PubMed ID: 29521683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dietary flavonoid and proanthocyanidin intakes and prostate cancer risk in a prospective cohort of US men.
    Wang Y; Stevens VL; Shah R; Peterson JJ; Dwyer JT; Gapstur SM; McCullough ML
    Am J Epidemiol; 2014 Apr; 179(8):974-86. PubMed ID: 24567173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
    Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
    BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum total and HDL cholesterol and risk of prostate cancer.
    Mondul AM; Weinstein SJ; Virtamo J; Albanes D
    Cancer Causes Control; 2011 Nov; 22(11):1545-52. PubMed ID: 21915616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study.
    Liu H; Shui IM; Platz EA; Mucci LA; Giovannucci EL
    Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1632-4. PubMed ID: 26189769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midlife metabolic factors and prostate cancer risk in later life.
    Dickerman BA; Torfadottir JE; Valdimarsdottir UA; Wilson KM; Steingrimsdottir L; Aspelund T; Batista JL; Fall K; Giovannucci E; Sigurdardottir LG; Tryggvadottir L; Gudnason V; Markt SC; Mucci LA
    Int J Cancer; 2018 Mar; 142(6):1166-1173. PubMed ID: 29114858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of vasectomy and prostate cancer among men in a Maryland cohort.
    Rohrmann S; Paltoo DN; Platz EA; Hoffman SC; Comstock GW; Helzlsouer KJ
    Cancer Causes Control; 2005 Dec; 16(10):1189-94. PubMed ID: 16215869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
    Stroup SP; Moreira DM; Chen Z; Howard L; Berger JH; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
    J Urol; 2017 Dec; 198(6):1309-1315. PubMed ID: 28709888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.
    Jacobs EJ; Rodriguez C; Bain EB; Wang Y; Thun MJ; Calle EE
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2213-7. PubMed ID: 17971518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
    Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
    BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.